Indivior PLC (INDV) Receives Consensus Rating of “Buy” from Analysts

Indivior PLC (LON:INDV) has been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is GBX 345.71 ($4.21).

A number of brokerages have recently issued reports on INDV. Jefferies Group upped their target price on shares of Indivior PLC from GBX 320 ($3.90) to GBX 330 ($4.02) and gave the stock a “buy” rating in a research report on Monday, August 1st. Numis Securities Ltd reiterated a “buy” rating and set a GBX 370 ($4.51) target price on shares of Indivior PLC in a research report on Wednesday, August 17th. Stifel Nicolaus reissued a “buy” rating and set a GBX 350 ($4.27) price target on shares of Indivior PLC in a research note on Wednesday, August 17th. Deutsche Bank AG boosted their price target on shares of Indivior PLC from GBX 290 ($3.53) to GBX 340 ($4.14) and gave the stock a “buy” rating in a research note on Thursday, August 11th. Finally, Royal Bank Of Canada boosted their price target on shares of Indivior PLC from GBX 185 ($2.25) to GBX 325 ($3.96) and gave the stock a “sector performer” rating in a research note on Tuesday, August 9th.

Shares of Indivior PLC (LON:INDV) traded down 2.29% during midday trading on Monday, hitting GBX 306.80. 1,864,523 shares of the company’s stock were exchanged. The company has a 50-day moving average of GBX 317.92 and a 200-day moving average of GBX 246.27. The firm’s market cap is GBX 2.21 billion. Indivior PLC has a 52 week low of GBX 126.60 and a 52 week high of GBX 365.00.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Michael Jordan Gains Ground on Getting His Name Back
Michael Jordan Gains Ground on Getting His Name Back
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday


 
© 2006-2016 Ticker Report. Google+.